Long-term follow-up cohort of hepatitis B in China: current status and perspectives
Hepatitis B virus (HBV) infection is a global public health issue, especially in the Asian-Pacific region. At present, entecavir, tenofovir, and pegylated interferon are the first-line antiviral drugs recommended by related guidelines for the prevention and treatment of hepatitis B; however, differe...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Hepatology
2017-08-01
|
| Series: | Linchuang Gandanbing Zazhi |
| Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=8371 |
| Summary: | Hepatitis B virus (HBV) infection is a global public health issue, especially in the Asian-Pacific region. At present, entecavir, tenofovir, and pegylated interferon are the first-line antiviral drugs recommended by related guidelines for the prevention and treatment of hepatitis B; however, different national/regional policies, economic level, coverage of health insurance, and medical level have caused the difference in antiviral regimens. Therefore, we have established a long-term follow-up cohort of hepatitis B to evaluate the efficacy of different treatment regimens, in order to improve the cure rate of hepatitis B and reduce the incidence rates of liver cirrhosis, liver cancer, and end-stage liver disease. Real-world data from cohort study help to understand the differences between guidelines and clinical practice, provide a reference for HBV guidelines, and balance clinical effect and cost-effectiveness.
|
|---|---|
| ISSN: | 1001-5256 1001-5256 |